Q1 2026 AngioDynamics Inc Earnings Call Transcript
Key Points
- AngioDynamics Inc (ANGO) reported a 12% revenue growth in Q1, driven by a 26% increase in the Med Tech segment.
- The Auryon platform continues to outperform, delivering double-digit growth for 17 consecutive quarters.
- Mechanical thrombectomy business grew over 40% year-over-year, with strong customer growth for both AlphaVac and AngioVac.
- NanoKnife revenue increased by 26.7%, supported by expanded prostate indications and upcoming CPT I code effectiveness.
- The company raised its fiscal 2026 revenue guidance, reflecting confidence in continued growth, particularly in the Med Tech segment.
- Despite revenue growth, AngioDynamics Inc (ANGO) reported an adjusted net loss of $4.2 million for the quarter.
- The company incurred $1.7 million in tariff expenses, impacting gross margins by approximately 220 basis points.
- Cash reserves decreased from $55.9 million to $38.8 million, with expectations of further cash utilization in Q2.
- The Med Device segment showed only a modest 2.3% growth, with expectations of low single-digit growth moving forward.
- The company faces ongoing challenges from tariffs, with an estimated $4 million to $6 million impact expected for the full fiscal year.
Good morning, and welcome to the AngioDynamics fiscal year 2026 first quarter earnings call. (Operator Instructions) As a reminder, this conference call is being recorded.
The news release detailing AngioDynamics' fiscal 2026 first quarter results crossed the wire earlier this morning and is available on the company's website. This conference call is also being broadcast live over the internet at the Investors section of the company's website at www.angiodynamics.com. A webcast replay of the call will be available at the same site approximately one hour after the end of today's call.
Before we begin, I'd like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events including statements about expected revenue, adjusted earnings and gross margins for fiscal year 2026, as well as trends that may continue.
Management encourages you to review the company's past and future filings with the SEC, including, without
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
